Renal tumor biomarkers (Review).
biological markers
blood and urine biomarkers
circulating tumor cells
molecular markers
renal cell carcinoma
Journal
Experimental and therapeutic medicine
ISSN: 1792-1015
Titre abrégé: Exp Ther Med
Pays: Greece
ID NLM: 101531947
Informations de publication
Date de publication:
Nov 2021
Nov 2021
Historique:
received:
05
05
2021
accepted:
04
06
2021
entrez:
11
10
2021
pubmed:
12
10
2021
medline:
12
10
2021
Statut:
ppublish
Résumé
One of the most common types of cancer worldwide (9th most commonly diagnosed) is renal cell carcinoma (RCC). It is more common in developed countries and it usually develops in individuals between 60 and 70 years of age. The earlier the disease is identified, the lower the morbidity. Therefore molecular markers that exist in blood and urine may be used for earlier detection and diagnosis but also for the follow-up of the patient after treatment, whether surgical or oncological. The trend is to analyze the gene and protein expression as they constitute a source for new biomarkers. These markers are promising but in clinical practice regarding disease management, they are rarely used. Biological markers can be employed in many tumors because they can identify the prognostic value for individual treatment. However, markers for RCC are not validated, and their analysis is currently under investigation. Previous findings have demonstrated that the metastatic potential of RCC can be predicted using the biological features of the tumor cell. It is believed that the transformation from epithelial to mesenchymal phenotype gives the tumor cell the ability to metastasize. The purpose of this review was to identify the most valuable tumor markers that can be clinically used for the prognosis, treatment and follow-up of patients with renal tumors.
Identifiants
pubmed: 34630652
doi: 10.3892/etm.2021.10732
pii: ETM-0-0-10732
pmc: PMC8461509
doi:
Types de publication
Journal Article
Review
Langues
eng
Pagination
1297Informations de copyright
Copyright © 2020, Spandidos Publications.
Déclaration de conflit d'intérêts
The authors declare that they have no competing interests.
Références
J Cell Physiol. 1984 Apr;119(1):29-34
pubmed: 6707100
Anticancer Res. 2012 May;32(5):1801-4
pubmed: 22593464
Oncotarget. 2014 Jan 30;5(2):506-18
pubmed: 24504108
Mol Clin Oncol. 2013 Jan;1(1):69-74
pubmed: 24649125
Investig Clin Urol. 2019 Nov;60(6):425-431
pubmed: 31692952
Science. 1997 Apr 4;276(5309):111-3
pubmed: 9082980
FEBS Lett. 2004 Nov 19;577(3):439-45
pubmed: 15556624
J Urol. 2013 May;189(5):1913-20
pubmed: 23154208
Clin Epigenetics. 2018 Jan 23;10:11
pubmed: 29410711
Pathology. 2014 Oct;46(6):518-22
pubmed: 25158810
Cancer Lett. 2015 May 1;360(2):114-8
pubmed: 25721081
Physiol Rep. 2017 Jun;5(11):
pubmed: 28596300
Br J Cancer. 2012 Feb 28;106(5):904-8
pubmed: 22294183
Br J Cancer. 2014 Oct 14;111(8):1526-31
pubmed: 25117808
Clin Cancer Res. 2004 Sep 15;10(18 Pt 2):6282S-9S
pubmed: 15448018
J Biol Chem. 1990 May 25;265(15):8361-4
pubmed: 1692830
Int Braz J Urol. 2018 Jan-Feb;44(1):38-44
pubmed: 28727370
J Clin Oncol. 2009 Oct 10;27(29):4834-8
pubmed: 19738116
Adv Exp Med Biol. 2014;816:197-234
pubmed: 24818725
FASEB J. 2008 Oct;22(10):3696-705
pubmed: 18614581
Cell Stress Chaperones. 2009 Jan;14(1):105-11
pubmed: 18663603
Eur Urol. 2009 Apr;55(4):851-63
pubmed: 19155123
J Urol. 2006 Dec;176(6 Pt 1):2353-8
pubmed: 17085101
Annu Rev Pathol. 2015;10:263-89
pubmed: 25387056
Annu Rev Immunol. 2011;29:235-71
pubmed: 21219185
Oncol Lett. 2013 May;5(5):1677-1681
pubmed: 23760084
Urology. 2010 Aug;76(2):513.e1-6
pubmed: 20573390
BMC Cancer. 2019 Jan 15;19(1):74
pubmed: 30646851
Int J Oncol. 2003 Sep;23(3):757-62
pubmed: 12888914
Br J Cancer. 2014 Apr 2;110(7):1778-84
pubmed: 24594997
Cancer. 2001 Nov 15;92(10):2493-500
pubmed: 11745181
Clin Cancer Res. 2009 Jan 15;15(2):650-9
pubmed: 19147771
Biomolecules. 2019 Jan 30;9(2):
pubmed: 30704117
J Urol. 2011 Oct;186(4):1206-12
pubmed: 21849193
Int J Biol Markers. 2019 Jun;34(2):176-183
pubmed: 31106654
Eur Urol. 2015 May;67(5):913-24
pubmed: 25616710
Oncol Lett. 2013 Jan;5(1):191-197
pubmed: 23255918
Cell. 2010 Mar 19;140(6):883-99
pubmed: 20303878